Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program-Reference-Cited by-同舟云学术

Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program

Published:2017-08 Issue: Volume:130 Page:180-185
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Gadzhanova Svetla,Pratt Nicole,Roughead Elizabet

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference18 articles.

1. NPS MedicineWise. Dapagliflozin (Forxiga) and canagliflozin (Invokana). NPS RADAR, Dec 2013.

2. Bristol-Myer Squibb Australia Pty Ltd. Dapagliflozin (Forxiga), Approved Product Information. 2012. .

3. Janssen-Cilag Pty Ltd. Canagliflozin (Invokana), Approved Product Information. 2013. .

4. Australian Government Department of Health. Pharmaceutical Benefits Schedule. Summary of Pharmaceutical Benefits. Summary of Changes. Effective 1 April 2015.

5. SGLT2 inhibitors: new medicines for addressing unmet needs in type 2 diabetes;Moses;Australasian Med J,2014

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial;Drug Research;2024-07-11

2. Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives;World Journal of Cardiology;2024-05-26

3. Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis;Journal of Renal Injury Prevention;2024-01-29

4. Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients;Scientific Reports;2023-10-27

5. Type 2 Diabetes Mellitus and its comorbidity, Alzheimer’s disease: Identifying critical microRNA using machine learning;Frontiers in Endocrinology;2023-01-19